Avène Taps AI to Revolutionize Dermo-Cosmetic Clinical Trials

TOULOUSE, France – March 11, 2026 – In a move that signals a significant shift for the dermo-cosmetics industry, Pierre Fabre Laboratories has announced that its leading brand, Avène, will pioneer the use of Artificial Intelligence to dramatically scale its clinical research. Partnering with French HealthTech firm BotDesign, Avène will leverage AI-driven data augmentation to expand a clinical study for a new acne treatment from 100 to 600 patients, setting a new precedent for scientific rigor in skincare.

The groundbreaking study, set to launch this year, will evaluate the efficacy of Avène Cleanance Comedomed+, a new treatment for acne-prone skin. Its focus is on a particularly challenging patient group: adults in the maintenance phase following a course of oral isotretinoin for severe acne. By synthetically and safely expanding its patient dataset, the company aims to generate more robust and reliable evidence than ever before for a dermo-cosmetic product.

A New Generation of Clinical Evidence

At the heart of this initiative is a sophisticated form of AI that generates synthetic patient data. Avène is collaborating with Toulouse-based BotDesign, a company specializing in AI solutions for healthcare. BotDesign's ORIGA platform uses generative AI and deep learning to create realistic, anonymized “artificial patients.” This process of data augmentation allows researchers to enhance existing datasets, improving the statistical power of a study without recruiting hundreds of additional real-world participants.

For Avène's 2026 study, this means the findings will be based on a cohort size more typical of pharmaceutical trials than dermo-cosmetic ones. Increasing the sample size from 100 to 600 drastically reduces the risk of random statistical noise and increases the likelihood of detecting a true treatment effect. The larger, AI-augmented dataset allows for more precise estimates of efficacy and could enable meaningful analysis of subgroups within the patient population.

While the broader beauty industry has begun to embrace AI for personalized product recommendations and marketing—with some brands using AI to generate more inclusive “before and after” visuals from clinical data—Avène’s application is distinct. This is a direct use of AI to augment the core scientific process of a clinical trial itself, a first for the dermo-cosmetics sector. This novel approach will likely face scrutiny from regulatory bodies, which are traditionally cautious about new methodologies. The success of the trial will depend on the transparent validation of BotDesign's algorithms and proving that the synthetic data accurately mirrors real-world patient profiles without introducing bias.

Beyond the Pill: The 'Supportive Care' Philosophy

This high-tech venture is a concrete manifestation of Pierre Fabre's overarching 'Supportive Care' strategy, a company-wide initiative launched in 2025. The strategy leverages the company's dual heritage in pharmaceuticals and dermo-cosmetics to create integrated treatment protocols that support patients through their entire healthcare journey.

"We belong to a group that has always been rooted in pharmaceuticals and dermo-cosmetics. Our medical expertise gives us a head start in understanding patients and their pathologies," explained Dr. Gautier Doat, Eau Thermale Avène Medical Director, in the company's official announcement. "We are ideally positioned to offer treatment protocols based on the pathology, combining dermo-cosmetics with medication. We are already preparing solutions to go further, by developing dermo-cosmetic innovations capable of extending and amplifying the action of the medication or delaying its necessity."

The choice of Avène Cleanance Comedomed+ for this pioneering study is a perfect illustration of this philosophy. Oral isotretinoin is a powerful and effective drug for severe acne, but managing the skin's health post-treatment to maintain results and prevent relapse is a critical, long-term challenge. By developing and rigorously testing a dermo-cosmetic product specifically for this maintenance phase, Avène is aiming to bridge the gap between intensive pharmaceutical intervention and long-term skin health. This approach seeks to amplify the benefits of the medication long after the prescription ends, a core tenet of the 'Supportive Care' vision which has also been applied to areas like oncology patient support.

AI as a Competitive Edge in the Acne Market

The global acne treatment market is a vast and fiercely competitive space, valued at approximately $10 billion in 2024 and projected to grow significantly. While dominated by pharmaceutical giants and a sea of over-the-counter options, Pierre Fabre is carving out a highly specialized and strategic niche. The focus on post-isotretinoin maintenance targets a specific, unmet need within the broader market.

Dermatologists stress the importance of a dedicated skincare routine after a course of isotretinoin to manage residual dryness and prevent relapse, yet dedicated, clinically-proven solutions for this phase are scarce. By investing in an AI-powered, large-scale study, Avène is not just launching another product; it is building a powerful evidence-based case for its efficacy in a specific, high-stakes medical context. The robust data generated from a 600-patient study could prove highly persuasive for dermatologists recommending maintenance therapies and for patients seeking to protect the hard-won results of their intensive treatment.

This investment in advanced clinical validation represents a significant strategic bet. It aims to differentiate Avène Cleanance Comedomed+ from competitors not just on formulation, but on the strength and scale of its scientific backing. If successful, this approach of combining a targeted dermo-cosmetic solution with AI-enhanced clinical proof could become a new gold standard in the industry, forcing competitors to re-evaluate their own research and development strategies. The move firmly positions Pierre Fabre at the intersection of technology, medicine, and consumer skincare, showcasing how digital innovation can be harnessed to deliver more effective and holistic patient care.